top of page
Search

WEEKLY REVIEW / Memorable Trades



Memorable trades executed with commentaries for this week.

November 11, 2024 to November 15, 2024

 

For this week an initial hypothetical investment of $10,000 yielded $24,328 (that's right -- $24,328)  in net gains from the companies of our memorable trades. Naturally, the fully documented results as stated may not represent future transactions, but if history is the judge, our G-101-SPM AI algorithm is the the best there is. Indeed, to make BIG MONEY in the stock market YOU MUST KEEP YOUR EYES ON THE BALL; be alert to the single most important fact --- information is "king" and who has the best gets the prize very single time.


PART ONE

 

11.15.24

$IONQ $28.48 +2.46 bid. DAC (dollar average cost after partial position liquidation the cost is zero).  EXIT $35.00.

Bullish option flow detected in IONQ(IONQ) with 31,630 calls trading, 1.4x expected, and implied vol increasing over 11 points to 127.28%. Nov-24 27.5 calls and Nov-24 30 calls are the most active options, with total volume in those strikes near 7,500 contracts. The Put/Call Ratio is 0.21.

 

11/14/24

$FREY $2.35 bid. DAC (dollar average cost) $1.65 (11.27.23). EXIT $4.00.

BRIEF:

1. FREY Chief Financial Officer bought 130,600 shares at $1.91 worth approximately $249K.

2. Reports Q3 (Sep) loss of $0.20 per share, excluding non-recurring items, $0.03 worse than the single analyst estimate of ($0.17). Reports no revenue.

As of September 30, 2024, FREYR had cash, cash equivalents, and restricted cash of $184.1 million, and no debt.

3. Acquire the U.S. solar manufacturing assets of Trina Solar Co ; expected to close year end 2024 ; 5 GW, 1.35 million square foot solar module manufacturing facility in Wilmer, Texas that started production on November 1, 2024.

note: Trina Solar is a global leader in solar and renewable energy industry with an established U.S. commercial presence, global supply chains, advantaged technology, and a strong track record of manufacturing and project execution for U.S. customers.

 

11.14.24

$BZH $36.77 +4.81 bid. DAC (dollar average cost) $34.06 (9.18.20.

CHANGE EXIT TO $44.00 FROM $40.00.

$0.34 better than the SPM consensus of $1.35; revenues rose 24.9% year/year to $806.2 mln vs the $775.42 mln consensus.

Net new orders for the fourth quarter increased to 1,029, up 2.6% from the prior year quarter, primarily driven by an 18.0% increase in average active community count to 153 from 130 a year ago, partially offset by a 13.0% decrease in sales pace to 2.2 orders per community per month, down from 2.6 in the previous year quarter.

Excluding impairments, abandonments and amortized interest, homebuilding gross margin was 20.4% for the fourth quarter, down 390 basis points year-over-year as a result of increased share of speculative home closings which generally have lower margins than "to be built" homes, changes in product and community mix, and an increase in closing cost incentives.

 

11.14.24

$RGTI $1.86 bid. DAC (dollar average cost) (4) $1.093 last $0.7912 (10.17.24). EXIT $4.50.

UPDATE: Rigetti’s recently announced 2025 roadmap, which features a new modular system architecture. By mid-year 2025, the Company expects to release a 36-qubit system based on four 9-qubit chips tiled together with a targeted 99.5% median 2-qubit fidelity. By the end of 2025, the Company expects to release a system with over 100 qubits with a targeted 99.5% median 2-qubit fidelity.

“We believe that superconducting qubits are the leading modality for high performance quantum computers. Rigetti’s system gate speeds consistently achieve an active duration of 60-80ns, which is several orders of magnitude faster than other modalities such as ion traps and neutral atoms. Our new multi-chip architecture will combine our strengths across our technology stack, and will be the result of our leadership in modular QPU design and performance optimization,” says Dr. Kulkarni.

 

11.14.24

$QUBT * $3.13 bid. DAC (dollar average cost) $1.39 (11.13.24).

CHANGE EXIT TO $8.00 FROM $6.00.

* QUBT as a BUY notice had a SPM 87.77 tag --- a high probability valuation for a "penny stock" and follows similar trend picks.

UPDATE: Today announced that the Company has secured its first order for its thin film lithium niobate (TFLN) photonic chip foundry. The order, placed by a prominent research and technology institute based in Asia, underscores the growing global demand for QCi's advanced fabrication technology of TFLN and its ability to produce high-performance photonic integrated circuits (PICs) and nanophotonic devices. This milestone highlights QCi's commitment to accelerating the widespread adoption of TFLN and positioning it as a vital component of the future telecom, datacom, and quantum landscape

11.13.24

$QUBT $2.58 +1.27 bid. DAC (dollar average cost) $1.39 (11.13.24). EXIT $6.00.

BRIEF: Ascendiant Capital analyst Edward Woo maintains Quantum Computing(QUBT) with a Buy and raises the price target from $8.25 to $8.50.

 

11.13.24

$GH $31.73 +2.00. * DAC (dollar average cost) (6) $26.46 last $23.00 (9.16.24). EXIT $50.00 (long term)

BRIEF: Revenue rose 34% to $191.5 million for the three months ending in September, blasting through the $170 million that analysts were modeling. Guardant Health also posted a much smaller loss than its shareholders were expecting. It also boosted its full-year guidance. note: With a balance sheet flush with cash and a promising pipeline of clinical or biopharmaceutical tests, Guardant Health is justifying its $50.00 EXIT.

* Click SEARCH (magnifying glass) icon on our landing page to review the postings.

 

11.13.24

$NNE $25.75 +2.85 bid. DAC (dollar average cost) $20.74 (10.30.24). EXIT $45.00.

CHANGE EXIT TO LEGACY HOLDING STATUS.

BRIEF: NANO Nuclear Space Inc. is planning commercial applications of the Company's developing micronuclear reactor technology in space.

 

11.13.24

$RXRX $7.88 +0.30. DAC (dollar average cost) $6.50 (8.8.24). EXIT $10.00.

BRIEF: Recursion Pharmaceuticals and Exscientia (EXAI) shareholders approve the proposed combination; transaction is expected to close on November 20, 2024.

note: Recursion expects to host an update call after the anticipated close on November 20, 2024 at 7:30 a.m. ET / 5:30 a.m MT / 12:30 p.m. GMT.

 

11.13.24

$SHLS $4.97 ask. BUY/* REVISIT carries SPM 87.04 tag to $8.50 in midterm.

* Click SEARCH (magnifying glass) icon on our landing page to review the postings. https://stocktwits.com/G101SPM/message/592315992

 

11.13.24

$CYBN $11.40 bid. DAC (dollar average cost) $9.37 (10.1.24). EXIT $15.00. BRIEF: Second Quarter Fiscal Year 2025 Financial Information: Cash totaled C$154.3 million as of September 30, 2024. ^With the completion of offerings and a combination of the Company's current cash position, and assuming the exercise in full of warrants issued pursuant to certain of the Company’s offerings, the Company has access to over C$217.7 million. ^Cash-based operating expenses consisting of research, general and administrative costs totaled C$24.8 million for the quarter ended September 30, 2024, compared to C$12.4 million in the same period last year. ^YB003 in development for the treatment of MDD has a total addressable market of >300 million people worldwide1 and 21 million in the U.S. 2 - ^Cash totaled C$154.3 million as of September 30, 2024.

 

11.13.24

$MRSN $2.38 bid. DAC (dollar average cost) $1.37 (8.13.24). EXIT $8.00 long term.

BRIEF: Reports Q3 (Sep) loss of $0.09 per share, $0.08 better than consensus of ($0.17); revenues rose 63.6% year/year to $12.6 mln vs the $7.53 mln.

Cash, cash equivalents and marketable securities as of September 30, 2024, were $155.2 million.

note: Mersana capital resources are sufficient to support its current operates into 2026.

 

11.13.24

Top prize for the week.

$IONQ $23.01 bid. * DAC (dollar average cost includes prior prior partial sales to reduce net cost to zero). EXIT on remaining position is $35.00.

UPDATE: IonQ announces the issuance of five new U.S. patents designed to deliver benefits across multiple industries and applications.

notes: New and pending patents reflect IonQ's leadership in quantum computing performance and scalability.

Technical highlights include a new method for control and flexibility in gate operations and a unique low-error technique for controlling gate operations.

* Click SEARCH (magnifying glass) icon on our landing page to review the postings. https://stocktwits.com/G101SPM/message/592304527

 

11.12.24

$NNE $22.59 +0.99 bid. DAC (dollar average cost) 20.64 (10.30.24). EXIT $45.00 (long term - pre-Legacy Holding status.

BRIEF: Today announced that it is one of just 16 civil nuclear entities joining the U.S. Civil Nuclear/SMR Industry Working Group (CNIWG) for Southeast Asia to support the deployment and export of U.S. small modular reactors (SMRs) and advanced nuclear technologies to Southeast Asia.

note: The CNIWG for Southeast Asia is an initiative established in partnership with the U.S. Department of Commerce’s International Trade Administration (ITA), the Foreign Commercial Service at U.S. Missions in Southeast Asia, and the Industry and Analysis (I&A) Office of Energy & Environmental Industries. It supports the objectives of ITA’s interagency SMR Public-Private Program (SMR PPP) to promote the deployment and export of U.S.-based advanced nuclear technologies, adhering to the highest standards of safety, security, and nonproliferation.

 

11.12.24

$IBRX $5.61 bid. DAC (dollar average cost) (6) $4.62 last $3.59 (10.23.24). EXIT $12.00.

UPDATE: Reports Q3 EPS of $(0.14), $0.04 better than the $(0.18) consensus estimate (3 estimates); total revenue of $6.1 mln vs. the $2.9 mln consensus estimate.

The U.S. launch of ANKTIVA for NMIBC CIS continues to gain momentum, and we are pleased to see the clinical impact for patients," said Richard Adcock, President and CEO of ImmunityBio. "Our permanent J-code has been issued by Centers for Medicare and Medicaid Services and will be effective January 1, 2025. Our submission of ANKTIVA for NMIBC CIS to the MHRA in the UK for potential approval demonstrates our plans for global expansion. Further, we anticipate an EU submission this quarter."

 

11.12.24

$AMPX $2.84 +0.40 bid. DAC (dollar average cost) (2) $1.52 (8.13.24). EXIT $7.00.

BRIEF: Amprius Technologies shipped SiMaxx A-Sample EV Cells to the United States Advanced Battery Consortium as requested based on superior performance:

note: USABC is a subsidiary of the United States Council for Automotive Research LLC (USCAR), the collaborative technology company of Ford Motor (F), General Motors (GM), and Stellantis (STLA).

Enabled by a cooperative agreement with the U.S. Department of Energy (DOE), USABC's mission is to develop electrochemical energy storage technologies that advance commercialization of next generation electrified vehicle applications.

 

11.11.24

$LYFT $18.96 +1,18 bid. DAC (dollar average cost) $11.27 (9.11.24).

CHANGE EXIT TO $26.00 FROM $16.00 on improved SPM. tag (current BRIEF not calculated with update on new EXIT).

BRIEF: Susquehanna analyst Shyam Patil maintains Lyft (LYFT) with a Neutral and raises the price target from $10 to $18

 

11.11.24

$BMBL $9.02 bid. DAC (dollar average cost) (16) $6.85 last $4.93 (8.8.24).

CHANGE EXIT TO $12.00 FROM $8.00 on improved SPM tag.

 

11.11.24

$NCNA $1.51 ask. BUY/ADD TO LONG POSITION carries SPM 75.95 tag to EXIT $10.00 (long term). DAC (dollar average cost includes 25% sale at $7.40 on 09.16.24 to reduce cost to $2.63 without consideration for current BUY).

UPDATE: NuCana plc (NASDAQ: NCNA) announced that initial data from the ongoing Phase 1b/2 modular study (NuTide:303) investigating NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors (Module 1) and in combination with docetaxel for patients with lung cancer (Module 2) have been published in MedRxiv, the preprint server for Health Sciences.

note: Encouraging signals of anti-cancer activity were observed with confirmed Partial Responses in 2 patients and Stable Disease in a further four patients, resulting in an objective response rate of 22% and a disease control rate of 67% in the efficacy evaluable population. The combination of NUC-3373 plus pembrolizumab was generally well tolerated.

 

11.11.24

$SPRY $17.89 bid. DAC (dollar average cost includes 50% sale of long position to reduce cost to zero). Original purchase was at $3.60 (9.22.23).

CHANGE EXIT TO $35.00 FROM $20.00 as Legacy Holding status.

UPDATE: ARS Pharmaceuticals announced a licensing agreement with ALK-Abelló A/S, that provides ALK exclusive rights to commercialize neffy (epinephrine nasal spray). ARS Pharma will receive an upfront payment of $145 million and is eligible to receive up to an additional $320 million in regulatory and sales milestones, as well as tiered, double-digit royalties in the teens on net sales in licensed geographies. ARS Pharma will be responsible for manufacturing and supplying neffy to ALK.

note: $SPRY 's intranasal epinephrine technology for the treatment of acute flares in patients with chronic urticaria, with plans to being a Phase 2b clinical trial in early 2025. The license agreement with ALK also provides them exclusive rights for any new indications in the licensed territories.


PART TWO

Our AI algorithm is an investment predictor that gathers data from 129 preset sources and presents the values as a SPM matrix number. The database tracks over 5215 individual stocks with each one carrying a "floating" SPM tag. The higher the value the greater the subjective probability of the collective data being accurate, and culminating with the issuance of an auxiliary SPM tag.


^Follow the daily abstracts: SPMNOTES, FIRSTLOOK, OPTIONACTION, INSIDERS, DILUTION, SHOWTIME, NOISE,  FLASHTRADE,  QUESTIONBOX and SURVEY.

^DAC means “dollar average cost” and determines the true cost of the investment position during the cycle of the trade.

IDEA: Devote quality time to understand how to apply the data as a "positional investor."

* Click https://stocktwits.com/G101SPM SEARCH on (magnifying glass) icon on our landing page to review the postings.

 

MISSION STATEMENT: To prove that non-human intervention by an analytical chatbot is far superior than the other kind. The rise of generative AI (GenAI) models, like OpenAI’s GPT, has accelerated our transformation. These tools do more than process data, G-101 SPM AI generates meaningful content, automate workflows, and unlock insights in ways traditional AI could never achieve.







ARE YOU READY TO MAKE BIG MONEY IN THE STOCK MARKET?



 



Recent Posts

See All

Comments


Newsroom

bottom of page